Dacheng Fund is one of the first ten fund companies established in China. Currently, it ranks more than 20 in the whole market. On the whole, it is an institution with relatively complete product line, strong investment and research strength and relatively balanced investment in stocks and bonds. It is one of the earliest "Top Ten" fund companies in China, but it is not developing very well now, and it can only be regarded as a third-rate Public Offering of Fund company.

In recent years, Dacheng's stock fund managers have been very active. Such as Han Chuang, Liu Xu and Xie. It is said that Han Chuang's performance is really good, and his net worth has risen too much. Watch it rise. Liu Xu is a prudent fund with a well-controlled retreat, which can be safely held for a long time.

Mainly in the "Chongqing Beer" incident, the personnel turmoil has not recovered. At the beginning of 2009, Lv Meng, a medical researcher of Dacheng Fund, found that the hepatitis B vaccine being developed by the subsidiary company of Chongqing Beer has made a "world-class" breakthrough. If the vaccine is successfully developed, it may bring a tenfold increase to Chongqing Beer. Dacheng Fund, which completed the research on Chongqing beer, started to act in the first quarter of 2009. According to public information, in the first quarterly report of Chongqing Beer in 2009, seven funds under Dacheng entered the first, third, fourth, fifth, sixth, seventh and ninth largest circulating shareholders of Chongqing Beer at the same time, holding a total of 38.88 million shares, accounting for 13.32% of the circulating capital. As a result, in the first quarter of 2009, the share price of Chongqing Beer rose by more than 50%.